| Item Type | Name |
|
Concept
|
Protein-Tyrosine Kinases
|
|
Concept
|
Protein Kinases
|
|
Concept
|
Mitogen-Activated Protein Kinases
|
|
Concept
|
MAP Kinase Kinase 7
|
|
Concept
|
src-Family Kinases
|
|
Concept
|
Receptor Protein-Tyrosine Kinases
|
|
Concept
|
MAP Kinase Kinase 4
|
|
Concept
|
Mitogen-Activated Protein Kinase 3
|
|
Concept
|
Cyclin-Dependent Kinase Inhibitor p16
|
|
Concept
|
MAP Kinase Kinase Kinase 4
|
|
Concept
|
Mitogen-Activated Protein Kinase Kinases
|
|
Concept
|
Cyclin-Dependent Kinase Inhibitor p21
|
|
Concept
|
Focal Adhesion Kinase 1
|
|
Concept
|
Protein Kinase C
|
|
Concept
|
TOR Serine-Threonine Kinases
|
|
Concept
|
MAP Kinase Kinase 6
|
|
Concept
|
Cyclin-Dependent Kinase Inhibitor p15
|
|
Concept
|
Phosphatidylinositol 3-Kinase
|
|
Concept
|
Cyclin-Dependent Kinases
|
|
Concept
|
MAP Kinase Signaling System
|
|
Concept
|
JNK Mitogen-Activated Protein Kinases
|
|
Concept
|
Janus Kinase 2
|
|
Concept
|
fms-Like Tyrosine Kinase 3
|
|
Concept
|
Protein Kinase Inhibitors
|
|
Academic Article
|
Overcoming cellular senescence in human cancer pathogenesis.
|
|
Academic Article
|
The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes.
|
|
Academic Article
|
Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea.
|
|
Academic Article
|
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study.
|
|
Academic Article
|
Alterations of the 9p21 and 9q33 chromosomal bands in clinical bladder cancer specimens by fluorescence in situ hybridization.
|
|
Academic Article
|
In vitro evaluation of calphostin C as a novel agent for photodynamic therapy of bladder cancer.
|
|
Academic Article
|
Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17.
|
|
Academic Article
|
Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers.
|
|
Academic Article
|
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
|
|
Academic Article
|
Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time.
|
|
Academic Article
|
Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.
|
|
Academic Article
|
Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.
|
|
Academic Article
|
Suppression of metastatic colonization by the context-dependent activation of the c-Jun NH2-terminal kinase kinases JNKK1/MKK4 and MKK7.
|
|
Academic Article
|
Targeted agents for the treatment of advanced renal cell carcinoma.
|
|
Academic Article
|
Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor.
|
|
Academic Article
|
Sorafenib in advanced clear-cell renal-cell carcinoma.
|
|
Academic Article
|
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
|
|
Academic Article
|
A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies.
|
|
Academic Article
|
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.
|
|
Academic Article
|
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
|
|
Academic Article
|
Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer.
|
|
Academic Article
|
Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC).
|
|
Academic Article
|
A phase I study of sirolimus and bevacizumab in patients with advanced malignancies.
|
|
Academic Article
|
FYN is overexpressed in human prostate cancer.
|
|
Academic Article
|
Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium.
|
|
Academic Article
|
Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers.
|
|
Academic Article
|
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
|
|
Academic Article
|
Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence.
|
|
Academic Article
|
Up-regulation of MKK4, MKK6 and MKK7 during prostate cancer progression: an important role for SAPK signalling in prostatic neoplasia.
|
|
Academic Article
|
Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells.
|
|
Academic Article
|
Pazopanib in renal cell carcinoma.
|
|
Academic Article
|
Increased p16 levels correlate with pRb alterations in human urothelial cells.
|
|
Academic Article
|
A G2/M growth arrest response to low-dose intermittent H2O2 in normal uroepithelial cells.
|
|
Academic Article
|
Monitoring anti-angiogenic therapy in colorectal cancer murine model using dynamic contrast-enhanced MRI: comparing pixel-by-pixel with region of interest analysis.
|
|
Academic Article
|
Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.
|
|
Academic Article
|
An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer.
|
|
Academic Article
|
Predictive markers in advanced renal cell carcinoma.
|
|
Academic Article
|
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.
|
|
Academic Article
|
A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy.
|
|
Academic Article
|
Maturing of renal cancer therapeutics.
|
|
Academic Article
|
Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib.
|
|
Academic Article
|
Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations.
|
|
Academic Article
|
Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).
|
|
Academic Article
|
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.
|
|
Academic Article
|
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study.
|
|
Academic Article
|
Eosinophilic renal cell carcinoma with isolated MTOR mutation metastatic to the liver: a novel case.
|
|
Academic Article
|
Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors.
|
|
Academic Article
|
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.
|